Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TYMP | P19971 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CCR10 | P46092 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12391050 | 0.90 | LMNA (0.57) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL11390072 | 0.89 | CA12 (0.64) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL8530813 | 0.85 | LMNA (0.59) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL2552403 | 0.82 | CA12 (0.57) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL11111165 | 0.82 | CA12 (0.57) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL8431954 | 0.82 | CA12 (0.61) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL11108846 | 0.82 | CA12 (0.57) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL13942803 | 0.82 | CA12 (0.57) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL7551284 | 0.82 | CA12 (0.48) | LMNATHRBCYP2C19CA12CA1 | |
| SCHEMBL6275193 | 0.82 | LMNA (0.47) | LMNATHRBCYP2C19CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4954515-A | RADIOSENSITIZING OR CHEMOSENSITIZING AGENTS IN THE TREATMENT OF HYPOXIC TUMOR CELLS | WARNER-LAMBERT COMPANY (US) | 1990-09-04 | — | — | US | claimed |
| CN-119431239-A | Compounds, pharmaceutical compositions, kits and uses thereof | 密执安大学评议会 | 2025-02-14 | — | — | CN | disclosed |
| CN-118949017-A | Compositions and methods for inhibiting T cell failure | 小利兰·斯坦福大学托管委员会 | 2024-11-15 | — | — | CN | disclosed |
| CN-113710241-B | Substituted bicyclic and tetracyclic quinones and related methods of use | 密执安大学评议会 | 2024-11-15 | — | — | CN | disclosed |
| CN-111727045-B | Compositions and methods for inhibiting T cell failure | 小利兰·斯坦福大学托管委员会 | 2024-07-19 | — | — | CN | disclosed |
| CN-111372934-B | Polymorphic forms of TG02 | 科瑞华生物技术有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-115947950-B | Micron-sized monocrystalline ZIFs and preparation method thereof | 电子科技大学长三角研究院(湖州) | 2024-02-27 | — | — | CN | disclosed |
| CN-117295716-A | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | 麦克尼斯迪克治疗有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
| EP-0302416-B1 | 2-NITROIMIDAZOLE DERIVATIVES USEFUL AS RADIOSENSITIZERS FOR HYPOXIC TUMOR CELLS | WARNER-LAMBERT COMPANY (US) | 1992-01-02 | — | — | EP | disclosed |
| EP-0302416-A1 | 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells | WARNER-LAMBERT COMPANY (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4797397-A | X-RAYS THERAPY OF TUMORS | WARNER-LAMBERT COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
| US-4456610-A | NEMATOCIDES | HOFFMANN-LA ROCHE INC. (US) | 1984-06-26 | — | — | US | disclosed |
| US-4366166-A | NEMATOCIDES | HOFFMANN-LA ROCHE INC. (US) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LMNA 4065/4885THRB 3189/4885CYP2C19 4419/4885 |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | ERCC2, CHEK1, ERCC4 | LMNA 2280/4885THRB 2144/4885CYP2C19 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.